143 related articles for article (PubMed ID: 11098095)
1. Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats.
Coudoré-Civiale MA; Courteix C; Fialip J; Boucher M; Eschalier A
Pain; 2000 Oct; 88(1):15-22. PubMed ID: 11098095
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of morphine and clomipramine analgesia by cholecystokinin -B antagonist CI-988 in diabetic rats.
Coudoré-Civiale MA; Courteix C; Boucher M; Méen M; Fialip J; Eschalier A; Ardid D
Neurosci Lett; 2000 May; 286(1):37-40. PubMed ID: 10822147
[TBL] [Abstract][Full Text] [Related]
3. Spinal effect of a neuropeptide FF analogue on hyperalgesia and morphine-induced analgesia in mononeuropathic and diabetic rats.
Courteix C; Coudoré-Civiale MA; Privat AM; Zajac JM; Eschalier A; Fialip J
Br J Pharmacol; 1999 Jul; 127(6):1454-62. PubMed ID: 10455296
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of intrathecally administered morphine and its interaction with cholecystokinin-B antagonist on thermal hyperalgesia following two models of experimental mononeuropathy in the rat.
Yamamoto T; Sakashita Y
Anesthesiology; 1999 May; 90(5):1382-91. PubMed ID: 10319787
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
Coudoré-Civiale MA; Méen M; Fournié-Zaluski MC; Boucher M; Roques BP; Eschalier A
Br J Pharmacol; 2001 May; 133(1):179-85. PubMed ID: 11325808
[TBL] [Abstract][Full Text] [Related]
6. The role of spinal cholecystokinin B receptors in thermal allodynia and hyperalgesia in diabetic mice.
Kamei J; Zushida K
Brain Res; 2001 Feb; 892(2):370-5. PubMed ID: 11172785
[TBL] [Abstract][Full Text] [Related]
7. Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine.
Singh L; Oles RJ; Field MJ; Atwal P; Woodruff GN; Hunter JC
Br J Pharmacol; 1996 Jul; 118(5):1317-25. PubMed ID: 8818359
[TBL] [Abstract][Full Text] [Related]
8. Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance.
Xie JY; Herman DS; Stiller CO; Gardell LR; Ossipov MH; Lai J; Porreca F; Vanderah TW
J Neurosci; 2005 Jan; 25(2):409-16. PubMed ID: 15647484
[TBL] [Abstract][Full Text] [Related]
9. The CCK-B receptor antagonist Cl 988 reverses tolerance to morphine in rats.
Hoffmann O; Wiesenfeld-Hallin Z
Neuroreport; 1994 Dec; 5(18):2565-8. PubMed ID: 7696605
[TBL] [Abstract][Full Text] [Related]
10. Supraspinal neurotensin-induced antianalgesia in mice is mediated by spinal cholecystokinin.
Holmes BB; Rady JJ; Smith DJ; Fujimoto JM
Jpn J Pharmacol; 1999 Feb; 79(2):141-9. PubMed ID: 10202849
[TBL] [Abstract][Full Text] [Related]
11. PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes.
Wiesenfeld-Hallin Z; Xu XJ; Hughes J; Horwell DC; Hökfelt T
Proc Natl Acad Sci U S A; 1990 Sep; 87(18):7105-9. PubMed ID: 1698290
[TBL] [Abstract][Full Text] [Related]
12. Differential modulation of alpha 2-adrenergic and opioid spinal antinociception by cholecystokinin and cholecystokinin antagonists in the rat dorsal horn: an electrophysiological study.
Sullivan AF; Hewett K; Dickenson AH
Brain Res; 1994 Oct; 662(1-2):141-7. PubMed ID: 7859067
[TBL] [Abstract][Full Text] [Related]
13. Dextromethorphan potentiates morphine antinociception, but does not reverse tolerance in rats.
Hoffmann O; Wiesenfeld-Hallin Z
Neuroreport; 1996 Feb; 7(3):838-40. PubMed ID: 8733757
[TBL] [Abstract][Full Text] [Related]
14. Increased spinal cholecystokinin activity after systemic resiniferatoxin: electrophysiological and in situ hybridization studies.
Broberger C; Farkas-Szallasi T; Szallasi A; Lundberg JM; Hökfelt T; Wiesenfeld-Hallin Z; Xu XJ
Pain; 2000 Jan; 84(1):21-28. PubMed ID: 10601669
[TBL] [Abstract][Full Text] [Related]
15. Activation of spinal cholecystokinin and neurokinin-1 receptors is associated with the attenuation of intrathecal morphine analgesia following electroacupuncture stimulation in rats.
Fukazawa Y; Maeda T; Kiguchi N; Tohya K; Kimura M; Kishioka S
J Pharmacol Sci; 2007 Jun; 104(2):159-66. PubMed ID: 17558184
[TBL] [Abstract][Full Text] [Related]
16. Magnesium increases morphine analgesic effect in different experimental models of pain.
Begon S; Pickering G; Eschalier A; Dubray C
Anesthesiology; 2002 Mar; 96(3):627-32. PubMed ID: 11873038
[TBL] [Abstract][Full Text] [Related]
17. CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level.
Xu XJ; Elfvin A; Hao JX; Fournié-Zaluski MC; Roques BP; Wiesenfeld-Hallin Z
Neuropeptides; 1997 Jun; 31(3):287-91. PubMed ID: 9243527
[TBL] [Abstract][Full Text] [Related]
18. Evidence for an exclusive antinociceptive effect of nociceptin/orphanin FQ, an endogenous ligand for the ORL1 receptor, in two animal models of neuropathic pain.
Courteix C; Coudoré-Civiale MA; Privat AM; Pélissier T; Eschalier A; Fialip J
Pain; 2004 Jul; 110(1-2):236-45. PubMed ID: 15275773
[TBL] [Abstract][Full Text] [Related]
19. Studies on the effect of systemic PD134308 (CAM 958) in spinal reflex and pain models with special reference to interaction with morphine and intrathecal galanin.
Wiesenfeld-Hallin Z; Xu XJ; Hughes J; Horwell DC; Hökfelt T
Neuropeptides; 1991 Jul; 19 Suppl():79-84. PubMed ID: 1715529
[TBL] [Abstract][Full Text] [Related]
20. Prevention of tolerance to the antinociceptive effects of systemic morphine by a selective cholecystokinin-B receptor antagonist in a rat model of peripheral neuropathy.
Idänpään-Heikkilä JJ; Guilbaud G; Kayser V
J Pharmacol Exp Ther; 1997 Sep; 282(3):1366-72. PubMed ID: 9316848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
